Subclinical Leaflet Thrombosis in Transcatheter Aortic Valve Replacement Detected by Multidetector Computed Tomography ― A Review of Current Evidence ―
View Full Paper
Ask AI
Bookmark
Share
Key result
Subclinical leaflet thrombosis after TAVR is increasingly recognized but clinical impact and antithrombotic management remain uncertain.
Population
Patients undergoing transcatheter aortic valve replacement at risk for or with subclinical leaflet thrombosis
Design
Review
Authors
Discussion
Loading...
Member takes
Implication
SLT post-TAVR prevalence and clinical impact remain uncertain; leaves open need for prospective studies before changing practice.
Structured PICO
P
Population
Patients undergoing transcatheter aortic valve replacement (TAVR) at risk for or with subclinical leaflet thrombosis (SLT)
This review highlights the emerging recognition of subclinical leaflet thrombosis post-TAVR and the need for clinical trials to define safe and effective antithrombotic management.
Limitations
- The actual prevalence of subclinical leaflet thrombosis is uncertain due to limited observational registries.
- There is uncertainty surrounding the clinical sequelae of subclinical leaflet thrombosis, leading to ambiguity in its management.
- Little data exist on the safety and efficacy of anticoagulation treatment for this condition.
Cite This Study
Rashid et al. (2018) conducted a review in Subclinical leaflet thrombosis following transcatheter aortic valve replacement. Transcatheter aortic valve replacement was evaluated. Subclinical leaflet thrombosis is increasingly recognized following transcatheter aortic valve replacement, though its clinical sequelae and optimal antithrombotic management remain uncertain.
Topics
View Full Paper
Ask AI
Bookmark
Share